Welcome to our dedicated page for CDT Equity SEC filings (Ticker: CDT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CDT Equity Inc. filings document a Nasdaq-listed biopharmaceutical issuer with common stock and redeemable warrants, a Delaware corporate structure, and an R&D-focused business built around clinical assets, intellectual property and strategic investments. Current reports and proxy materials cover material agreements, Sarborg-related securities transactions, equity line arrangements, warrant issuances, resale registration obligations and Nasdaq shareholder-approval matters.
The filing record also addresses capital-structure changes such as reverse stock split amendments, voting results, director appointments, committee membership and Exchange Act reporting status, including annual-report timing notices. These disclosures describe CDT's governance framework, security-holder rights and financing tools.
CDT Equity Inc. Schedule 13G reports a group of affiliated entities and individuals collectively associated with Ascent Partners Fund LLC that hold or have rights to 543,645 shares of Common Stock, representing 9.9% of the class based on 4,858,350 shares outstanding as reported in the Prospectus. The shares comprise the maximum issuable under a Directed Stock Purchase Agreement dated January 16, 2026 (the "ELOC Agreement") and are subject to a 9.99% beneficial ownership limit (the "Blocker"). As of June 5, 2026, Ascent holds no shares directly, there are 543,645 shares issuable under the ELOC Agreement (the Blocker maximum), and an internal reorganization on June 1, 2026 moved management such that Dominion Capital Holdings LLC ceased to hold voting or dispositive power and Eagle Claw became a >5% beneficial owner.
CDT Equity Inc. reported receiving a Nasdaq deficiency notice because it did not file its Form 10‑Q for the quarter ended March 31, 2026 on time, as required by Nasdaq Listing Rule 5250(c)(1) governing periodic filings. The notice does not immediately affect trading or the listing of its common stock or warrants on The Nasdaq Capital Market.
Nasdaq has given the company until July 20, 2026 to submit a plan to regain compliance. CDT Equity anticipates filing the delayed Form 10‑Q once its review process is complete, which it expects will restore compliance with the periodic filing requirement.
CDT Equity Inc. Schedule 13G: a Nirland/Stockton/Rowland/Dovet group reports shared beneficial ownership of 75,315 shares of Common Stock, equal to 1.6% of the class. The group states it exceeded 5% on 02/19/2026, which triggered the reporting obligation; ownership has since decreased below 5% as of this filing. The filing lists shared voting and dispositive power for 75,315 shares and includes a Joint Filing Agreement dated 05/20/2026.
CDT Equity Inc. submitted a Form 12b-25 notification that its Quarterly Report on Form 10-Q for the period ended March 31, 2026 could not be filed on time. The company says it could not, without unreasonable effort or expense, compile all financial statement information and expects to file the Form 10-Q on or before the fifth calendar day following the prescribed due date.
The filing discloses the company anticipates stockholders' equity will increase from a deficit as of December 31, 2025 and that the company will report a greater loss for the quarter versus the year‑ago period; amounts remain under review. The notification is signed by CEO Andrew Regan on May 15, 2026.
CDT Equity Inc. entered into amendments to its equity line of credit and a related senior secured convertible note. The company and its institutional investor set the gross purchase price for each regular ELOC closing, without purchaser consent, at $510,000. The note amendment allows the company to retain 90% of proceeds from any debt or equity financing, including the ELOC, while 10% must be applied to amounts due under the note. Both amendments are effective through May 31, 2026 and then cease to modify the original agreements.
Corvus Capital Ltd. and Andrew Regan filed Amendment No. 5 to their Schedule 13D on CDT Equity Inc., updating their ownership following recent share issuances and purchases. Corvus now beneficially owns 257,166 common shares, representing about 5.3% of the outstanding stock, while Dr. Regan beneficially owns 262,766 shares, or about 5.4%.
On March 24, 2026, CDT Equity issued Corvus 147,401 shares through a cashless exercise of all its Pre-Funded Warrants, after a 1-for-25 reverse stock split of its common stock. On May 13, 2026, Corvus purchased 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, funded with cash on hand. The filing states the CDT shares were acquired for investment purposes.
CDT Equity Inc. director and CEO Dr. Regan reported indirect purchases and conversions through affiliated entities. On March 24, 2026, Corvus Capital Limited, which he controls, exercised all its pre-funded warrants via cashless exercise into 147,401 shares of Common Stock, eliminating the warrant position. On May 13, 2026, Corvus bought an additional 100,000 shares in the open market at $1.90 per share for total cash consideration of $190,000, bringing Corvus’s reported Common Stock holdings to 256,393 shares. Separate indirect holdings via Manoira Corporation total 773 shares, and Dr. Regan also holds 5,600 shares directly. All share amounts reflect a 1‑for‑25 reverse stock split effected on March 26, 2026.
CDT Equity Inc. registers 5,348,058 shares of Common Stock for resale by selling stockholders. The registration covers 925,925 shares issuable under an amended equity line of credit with Ascent Partners Fund LLC and 4,422,133 shares issued in connection with the Sarborg Limited purchase transaction. The Company states it will not receive any proceeds from sales by the selling stockholders and the shares may be sold from time to time at market, negotiated or private prices. The prospectus notes a 1-for-25 reverse stock split effective March 26, 2026 and references an ELOC capacity of $25.0 million.
CDT Equity Inc. director Olsen Ulrik K filed an initial Form 3 reporting his holdings of the company’s Common Stock. The filing shows direct ownership of 233,585 shares, establishing his baseline equity position as an insider. The filing does not reflect any new buy or sell transactions.